Category Archives: Cervical Cancer

[Coriolus versicolor–innovation in prevention of oncogynecological diseases, especially HPV]

Akush Ginekol (Sofiia). 2008;47 Suppl 3:51-3.

[Article in Bulgarian]

Bogdanova J.

Abstract

Coriolus-MRL is a nutrient adjuvant, which contains biomass of the fungus Coriolus versicolor and is studied to reverse early stages of cervical cancer and to reduce risk factors of reoccurring HPV virus.

PMID: 19449722 [PubMed – indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/19449722

Coriolus Versicolor is Potent Mushroom for Fighting Cancer and Autoimmune Diseases – By: Barbara L. Minton, citizen journalist

(NaturalNews – January 28, 2009) For thousands of years Chinese medicine has prized the mushroom for its energizing and healing properties. Chinese legend is filled with stories of those who discovered the 1,000 year old mushroom and became immortal. In the West, acceptance is based less on tradition and more on the results of the scientific method. Researchers have been busy scientifically documenting what Chinese tradition dictates, that mushrooms are some of the most potent medicines on the plant. Recent research findings have shown the Coriolus versicolor mushroom stands out above the rest for regulating the immune system.

Coriolus versicolor found to be effective against cancer and human papillomavirus

Researchers at the Sloan-Kettering Cancer Center in New York tested several botanicals for their immune enhancing activity using a subcutaneous immunization model of cell surface carbohydrate expression in cancer cells in a study published in September, 2008 Vaccine. They found Coriolus versicolor to display consistent and significant immune enhancement activity superior to all other coumpounds tested. The superiority of Coriolus to yeast beta-glucan, maitake, turmeric, echinacea, and preparation H-48 from Honso USA, was described as surprising. Although the exhibited levels of immune enhancing ability of astragalus was also impressive, it was surpassed by that of Coriolus.

The March, 2008 BMC Cancer reports Coriolus versicolor has shown anticancer activity with positive results in the treatment of gastric, esophageal, colorectal, breast and lung cancers. The efficacy of its protein-bound polysaccharide as an immunomodulator is credited. This activity was independent of its previously described immunomodulatory effect on NK cells.

The journal Cancer Immunology and Immunotherapy reports double blind trials on 111 patients with colorectal cancer, using Coriolus versicolor. Although traditional medicine offers little help for colon cancer patients, Coriolus showed a remarkable enhancement of the patient’s white blood cells, even in advanced colon cancer cases. The white cells greatly increased natural chemotactic motion and phagocytosis, the ability to scavenge toxins and kill pathogens. Coriolus was also used with patients as a helpful maintenance therapy following cancer surgery.

The results of a year long clinical trial examining the effects of mushroom supplementation in patients with Human Papillomavirus (HPV) were so impressive they were presented in 2008 at the 20th European Congress of Obstetrics and Gynocology. Dr. Silva Couto and his research team found that Coriolus versicolor supplementation over the period of one year substantially increased regression of dysplasia and induced clearance of the high-risk subtypes of the HPV responsible for cervical cancer. Coriolus supplementation demonstrated a 72 percent regression rate in lesions compared to 47.5 percent without supplementation, and a 90 percent regression rate in the high risk HPV virus sub-types compared to 8.5 percent without.

After using the supplement for one year, 72.5 percent of recipients reverted to normal cytology compared with only 47.5 percent of the control group. Coriolus supplementation produced a 90 percent regression rate in the high risk HPV virus sub-tupes compared to an 8.5 percent regression without supplementation.

It is also likely that Coriolus versicolor would be beneficial in high-grade squamous intraepithelial lesion (HSIL), a precancerous condition in which the cells of the uterine cervix are moderately or severely abnormal. The lead physician of the study noted that the optimal supplementation period may be as short as six months.

Coriolus versicolor modulates autoimmune diseases

T cells belong to a group of while blood cells known as lymphocytes, and play a central role in cell-mediated immunity. The activation of T helper (Th) cell subsets also plays an important role in immunity. Uncontrolled Th responses lead to autoimmune and inflammatory diseases. The identification of agents that modulate these helper cells is essential for controlling autoimmune diseases. A study from the November, 2008 Journal of Pharmacy and Pharmacology, reported that polysaccharopeptide (PSP) from Coriolus versicolor exhibited the ability to control aberrant T lymphocyte activation through ciclosporin-like activity. PSP alone suppress production of activated T cells.

What makes Coriolus versicolor special?

Coriolus versicolor, also referred to as the turkey-tail mushroom, contains large quantities of Beta-glucans that act to stimulate the immune system. Coriolus can dramatically regenerate and rejuvenate the body. Its most active medicinal components are biological response modifiers called protein-bound polysaccharides. These polysaccharides are known as Krestin or PSK in Japan, and as Yun zhi, or PSP in China. There have been reports of cases of Bell’s palsy clearing up with use of Coriolus for just a few days. Others have found it effective against bronchitis.

Other studies have shown that Coriolus can double the number of natural killer cells after only 8 weeks of treatment. Coriolus has also been found to help patients with chronic fatigue syndrome and may be an effective treatment for Lyme disease.

More research documents the anti-tumor benefits of Coriolus

Japanese researchers screened 200 of the best phytochemicals (plant extracts) known for anti-tumor activity. Coriolus versicolor was designated as exhibiting the greatest amount of anti-tumor activity. In another Japanese study, 185 people with lung cancer at different stages were given radiation. Doctors found those who also took Coriolus showed the best tumor shrinkage and the best survival rate. Another study involving stomach cancer patients produced similar results. Those who received Coriolus survived significantly longer, felt better and had fewer side effects.

Coriolus is first line defense against infection

Coriolus is a good centerpiece for your natural medicine chest, even if you are currently the picture of health. When any type of infection strikes, you will be ready. Coriolus can be used to target any infected organ, gland or tissue. Its immune enhancing properties provide an increased response to deal effectively with infections, and do this without over stimulating the immune system.

Sources:

Clinical Trial Results Show Proof of Concept for Use of Coriolus Versicolor As Immunonutrition in IPV Patients With Cervical Lesions, Medical News Today.

Coriolus, www.cocoonnutrition.org.

Coriolus Versicolor, University of California, San Diego Complementary and Alternative Therapies for Cancer Patients.

About the author

Barbara is a school psychologist, a published author in the area of personal finance, a breast cancer survivor using “alternative” treatments, a born existentialist, and a student of nature and all things natural.

Source: NaturalNews – http://www.naturalnews.com/025455.html

Clinical Trial Results Show Proof-of-Concept For Use Of Coriolus Versicolor As Immunonutrition In HPV Patients With Cervical Lesions (LSIL)

(Medical News Today – 4/29/2008) The results of a year long clinical trial examining the effects of mushroom supplementation in patients with Human Papillomavirus (HPV) have recently been presented at congress. Dr. Jose Silva Couto and Dr. Daniel Pereira da Silva of the Cervical Pathology Unit of the Portuguese Institute of Oncology in Coimbra, Portugal presented their findings at the 20th European Congress of Obstetrics and Gynaecology, in Lisbon Portugal. This study provides a promising set of results and demonstrates proof-of concept for the question as to whether immunonutrition supplements can be successfully used to improve HPV status in patients.

The poster presentation detailed the results of the evaluation of the Efficacy of Coriolus versicolor Supplementation in patients infected with HPV with low-grade squamous intraepthithelial lesions (LSIL). The Coriolus versicolor mushroom supplied for the study was produced by Mycology Research Laboratories Ltd in tablet form (500 mg/tablet).

Dr. Silva Couto et al. found that Coriolus versicolor supplementation over a period of one year substantially increased regression of the dysplasia (LSIL) and induced clearance of the high risk sub-types of the HPV virus responsible for cervical cancer.

a) Coriolus versicolor supplementation demonstrated a 72% regression rate in LSIL lesions compared to 47.5% without supplementation.

b) Coriolus versicolor supplementation demonstrated a 90% regression rate in the high risk HPV virus sub-types compared to 8.5% without supplementation.

Study Design

The year long study was funded by Mycology Research Laboratories Ltd. The Portuguese pharmaceutical firm Aneid-Produtos FarmacĂȘuticos Lda acted as collaborative partners.

Forty-three (43) patients with HPV Lesions (LSIL) were divided into two groups:

– A Control group (21 patients) who did not receive any treatment

– A treatment group (22 patients) who each received Coriolus versicolor supplementation for a period of one year (6 tablets/day i.e. 3g/day)

Protocol Design

At first observation, patients were examined with colposcopy, biopsy and HPV tipification (hybrid capture). Cervical cytology exams (Pap smear tests) determined the patients’ LSIL status and this was confirmed through colposcopy and biopsy.

Four months after the first observations, colposcopy and cervical cytology was again carried out on all patients. At the same time, there was an evaluation of the possible side effects from Coriolus supplementation.

After one year, (at the end of the supplementation period), colposcopy, cervical cytology and HPV typing were carried out on all patients.

Success Parameters

The authors measured the efficacy of Coriolus supplementation in LSIL patients in terms of the evolution of HPV status from High Risk HPV+ status to High Risk HPV- status. High Risk HPV, refers to certain strains of HPV that are known to be associated with causing cervical cancer, such strains include HPV 16, 18, 31 and 45. The persistence of cervical lesions as measured by colposcopy and cytology was also determined.

Study Population

Out of the 43 patients enrolled, 39 completed the trial. Of the four (4) who did not complete the trial, 1 patient left the country and 3 discontinued supplementation due to mild side-effects. The side-effects were not serious and did not warrant further medical intervention.

The age distribution of the two groups was very similar. Patients receiving Coriolus versicolor supplementation had an average age of 31.7 years (minimum age of 19, maximum age of 49 years). The control group had an average age of 33.4 years (minimum age of 19 and a maximum of 51 years).

Results

Of the 39 patients who completed one year of follow-up, 18 took Coriolus supplementation, while the other 21 patients received no therapy (Control group). After 1 year 13 of the 18 patients in the Coriolus group showed normal cervical cytology (72.5%) while only 10 of the patients in the control group did (47.5%).

Of the 39 patients, 22 were positive for high risk HPV subtypes.10 of these patients were in the Coriolus group and 12 in the control group. After 1 year 9 of the 10 in the Coriolus group had reverted to HPV- status (90%) while only 1 of the 12 in the control group had (8.5%).

What do these results mean for HPV patients?

The results from this study are encouraging and provide insight into the effectiveness of Coriolus versicolor as a useful immunonutrition agent. Using Coriolus supplementation for one year resulted in 72.5% of recipients reverting to normal cytology compares with only 47.5% of the control group. Encouragingly, 90% of the Coriolus recipients reverted to a HPV- status compared with only 8.5% in the control group.

While the study sample size is limited in number, the results strongly suggest that using Coriolus versicolor as a food supplementation agent offers doctors a useful nutritional tool when treating HPV (LSIL) patients over the age of 35 or those HPV (LSIL) patients with compromised immune systems.

It is also likely that Coriolus versicolor could be beneficial in HSIL patients who have undergone surgery but who experience recurrent lesions caused by persistent HPV viral infection; the eradication or “control” of the viral infection is key to both LSIL and HSIL patient care.

According to Dr Silva Couto, one of the study authors “At present, we believe that the optimal supplementation period may actually be as short as six months. Further testing is required to determine the best way to reduce the time period from the one year period used in this study.”. A shorter period of treatment would aid compliance as well as reducing the already minimal overall cost of therapy.

Why Coriolus versicolor?

As already stated, the mushroom Coriolus versicolor has been used in traditional Asian medicine for a long time. It is now known that Coriolus contains high quantities of Beta-glucans that act to stimulate the immune system. Studies have shown that Coriolus can double the number of natural killer cells after only 8-weeks of treatment.1,2 The benefits of treatment with the fungus has also been tested in patients with chronic fatigue syndrome. Coriolus versicolor (strain CV-OH1) is grown aseptically on sterile, edible grain, harvested and then produced as a tablet following good manufacturing practice according to pharmaceutical guidelines. It is free from pesticide, heavy metals and contaminants.

1. Jean A. Monro, Chronic Fatigue Immune Dysfunction Syndrome. J Integrative Medicine 2004;8:101-108

2. Jean A. Monro Treatment of Cancer with Mushroom Products. Arch Env Health 2003;58:533-537

Source: Medical News Today
http://www.medicalnewstoday.com/articles/105573.php